Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(4):290-291; doi:10.1093/jnci/92.4.290
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jatoi, A.
Right arrow Articles by Goldberg, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jatoi, A.
Right arrow Articles by Goldberg, R. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 4, 290-291, February 16, 2000
© 2000 Oxford University Press

EDITORIALS

Is ATP (Adenosine 5'-Triphosphate), like STP®, a Performance-Enhancing Additive for the Tanks of Cancer Patients?

Aminah Jatoi, Charles L. Loprinzi, Jeffrey Sloan, Richard M. Goldberg

Affiliations of authors: A. Jatoi, C. L. Loprinzi, R. M. Goldberg (Division of Medical Oncology), J. Sloan (Division of Biostatistics), Mayo Clinic, Rochester, MN.

Correspondence to: Richard M. Goldberg, M.D., Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905 (e-mail: goldberg.richard@mayo.edu).

Among 1000 patients with advanced cancer, Donnelly and Walsh (1) found that anorexia, weakness, and weight loss (>=10% of premorbid weight) were among the 10 most bothersome signs and symptoms. Despite the impact of the cancer anorexia/cachexia syndrome, relatively few clinical trials target its palliation as their primary end point. Observations that the drugs megestrol acetate, dexamethasone, and cyproheptadine caused unwanted weight gain when they were used to treat other illnesses led to clinical trials in cancer patients with anorexia/cachexia. In this setting, these agents may stimulate appetite and permit some patients to regain weight but do not appear to . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
A. Jatoi, B. D.T. Daly, V. A. Hughes, G. E. Dallal, J. Kehayias, and R. Roubenoff
Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?
Ann. Thorac. Surg., August 1, 2001; 72(2): 348 - 351.
[Abstract] [Full Text] [PDF]